Precision and Escalation: The 2026 Strategic Outlook for the Small Cell Lung Cancer (SCLC) Treatment Market
As of early 2026, the small cell lung cancer (SCLC) treatment market has transcended its historical reputation as a “recalcitrant” therapeutic area. Once defined by decades of clinical stagnation, the sector is now one of the fastest-growing oncology verticals, projected to reach a $5.1 billion valuation by 2032. This expansion is catalyzed by the transition … Read more